The third phase of clinical trials involving the drug remdesivir is underway at University Hospital and UT Health San Antonio. The National Institutes of Health is sponsoring the Adaptive COVID-19 Treatment Trial 3. In this trial, remdesivir will be paired with interferon beta-1A, which has the approval of the U.S. Food and Drug Administration for treating multiple sclerosis patients.